Scouting report · NTRA

Steven L. Chapman

Joined Natera in 2010 as a sales VP; CEO and President since January 2019

Born / age
(46)
Role
Chief Executive Officer, President and Director
In the role
8 yr
Education
BS University of California, Los Angeles
Front Office rank
not ranked yet
NTRA
Natera, Inc.Diagnostics
Title
Chief Executive Officer, President and Directorsrc
In role
since 2019-01 (8 yr)
Stake value—no holding or price on file
—thin record

Scouting sheetas of 24 Sep 2026

Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design5550% performance-conditioned · revenue, margin, fcf, time only · 98% for · company lost money
Skin in the game—no holding or price on file
—Hit rate
50%Pay at risk
98%Say-on-pay
—Airtime on calls
Beat
0
Met
0
Missed
0
Withdrawn
0
Still open
0
Answers on calls
0
Questions dodged
0
Dodges / 100 answers
—

Personal and ownership data

Full name
Steven L. Chapman
Age
46src
Education
BS Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles (2002)src

Not on file yet: born, place of birth, citizenship, marital status.

Shares held
32,401 NTRA, 2026-03-15src
Share of company
0.02%
Traded, 12 months
bought $0, sold $94.0msrc
Last pay
$15.0m 2025src
Pay at risk
50%
Say-on-pay vote
98.0% forsrc
CEO pay ratio
101 : 1

What to weigh

Watch 5

  • Personal defendant in a certified securities class action (Rule 10b-5, class period 2020-02-26 to 2022-03-14). The complaint alleges he, Brophy and Rabinowitz sold stock while holding material non-public information. These are allegations, not findingssrc
  • On his watch a jury found Natera liable for false advertising against Guardant Health, with $292.5m of damages (Nov 2024). The court largely upheld the verdict in July 2025 and Natera plans to appeal. A 2022 CareDx false-advertising verdict of $44.9m against Natera was set aside, and the Third Circuit affirmedsrc
  • Little skin in the game: 32,401 shares beneficially owned (16,767 held plus 15,634 vesting within 60 days), under 0.1% of the company, after about $94m of stock sales in the last 12 monthssrc
  • 2025 bonus target for revenue was set at $1,883.2m, about 11% growth. Actual growth was 35.9%, so the company element paid 131.1%. His bonus is 100% company metricssrc
  • Total 2025 pay of $14.96m, a 101:1 CEO pay ratio, in a year the company lost $208.2m under GAAPsrc

In their favour 2

  • Say-on-pay passed with about 98% of votes cast for or against at the June 2026 meetingsrc
  • Half of his target pay is performance-based (PSUs on a three-year cumulative revenue goal). Base salary stays below peer median, at the 30th percentile in 2025src

Pay

Salary and otherBonus, stock, options, incentive

  • $12.7m2023
  • $13.0m2024
  • $15.0m2025
The table
YearSalaryBonusStockOptionsIncentiveOtherTotal
2023$751k$0$11.1m$0$834k$10k$12.7msrc
2024$800k$0$11.3m$0$938k$10k$13.0msrc
2025$854k$0$13.0m$0$1.1m$10k$15.0msrc
Bonus pays on
Cash incentive at 100% of salary target, 100% on company metrics: revenue 55%, product gross margin 35%, operating cash flow 10%; paid 131.1% for 2025, delivered as fully vested RSUs
Long-term award pays on
50% PSUs vesting on a three-year cumulative revenue goal, 50% time-based RSUs vesting over four yearssrc
  • Pay at risk 50% performance-conditioned
  • Pays on returns revenue, margin, fcf, time only
  • Shareholder vote 98% for
  • Pay vs profit company lost money

CEO pay ratio 101 : 1

Career

  1. 2019 – now
    Naterasrc
    Chief Executive Officer, President and Director
    Appointed effective 2019-01-02 when co-founder Matthew Rabinowitz stepped down as CEO and became Executive Chairman
  2. 2017 – 2019
    Naterasrc
    Chief Operating Officer (from July 2017); Chief Commercial Officer (from March 2017)
  3. 2010 – 2017
    Naterasrc
    Vice President of Sales; Vice President, Commercial Operations
    Joined December 2010
  4. 2003 – 2010
    Genzyme Genetics Corp.src
    Commercial role (the filings do not give the title)
  5. 2002 – 2003
    UCLA, Department of Human Geneticssrc
    Researcher (first job)
    The proxy gives no dates; the years are inferred from the 2002 class year (WS-ucla) and the 2003 Genzyme start

Not located: Title at Genzyme Genetics (2003-2010) not stated in any filing; UCLA research dates inferred, not stated

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Background

  • Family The 2026 proxy states the only family relationship among directors and executive officers is the Rabinowitz brothers. Director Rowan Chapman, who chairs the human capital committee that sets his pay, is therefore not a relative per the proxysrc
  • Boards Director of the American Clinical Laboratory Association (ACLA), the lab-industry trade groupsrc
  • Other A scientist by training who came up through sales: began as a human-genetics researcher at UCLA, then seven years in the commercial organisation at Genzyme Genetics before Naterasrc
  • Legal Named as a defendant, with Natera, Brophy and Rabinowitz, in the securities class action in the Western District of Texas (filed April 2022, amended October 2022) over statements about Prospera and Panorama. The motion to dismiss was granted in part and the court has certified the classsrc

Sources11